* BIOQUANTA *
2002 - IDF
Paris
www.bioquanta.com Contract, Research
(also, Discovery, Drugs)
Key words: Angiogenic drug, In Silico subcontractor, Bio-informatics, MultiDIP
Mission: to offer in silico services and biological services for the selection and improvement of third parties' potentially therapeutic compounds, by predicting their toxicity, bioavalability ADME and profile
Clients: Biotech companies, Pharmaceutical, Food and Cosmetics industries
info@bioquanta.net
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture |
Managing Dir.: Mauclaire (Jean-Michel) [born 1957, co-founder, Sup de Co (Paris), CPA Accounting, ex-Lindsey, Lafarge]
Sc.Dir.:
Fin.Dir.: Cottin (Jean-Matthieu) [Sup de Co (Paris), ex-Eli Lilly, Nutricia]
BusDev: Boudières (Daniel)
Financers: privately-owned (undisclosed private investors) | Turnover (M€) : 0.19 (2007)
Total funding (M€) : 0.05
Last funding (M€) : 0.05
Focus : Cancers
Position : Patents
Company confirm : 30-Sep-2008 |
History | DATE | MILESTONE | TYPE | TIME | | 2006 .03 | Set-up of BioQuanta Diagnostics | ORGC | [4 years] |
| 2003 .04 | Seed financing : undisclosed M€, by private investors | SFIN | [1 year] |
| 2003 .02 | Set-up of subsidiary in France (SaRL) | ORGC | [1 year] |
| 2002 .12 | Company founded by Jean-Michel Mauclaire and others, in Aurora (USA) as BioQuanta Inc. | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|
